Trial · NCT06144060
A Trial of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritis
NCT06144060, Phase 2, Unknown, Jiangsu HengRui Medicine Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Trial of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritis. Trials, record NCT06144060. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06144060
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Trial of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritis
- NCT number
- NCT06144060
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 126 participants, estimated
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Conditions
- Patients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)
- Interventions
- HRS -8427, Imipenem and Cilastatin Sodium
- First posted
- 2023-11-22
- Last updated
- 2023-11-22
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Test of Cure (TOC) | Test of cure (TOC; 7 days after end of treatment [EOT], equivalent to Study Day 14 to 21) | |
| Secondary | Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Early Assessment（EA）、End of Treatment（EOT）and Late Follow-Up (LFU) | EA : Day 4、EOT: Day 7 to Day 14、LFU：Day 21 to Day 28 | |
| Secondary | Percentage of Participants With Microbiological Eradication at EA（Day 4） 、EOT（End of treatment）、TOC（7 days after end of treatment） and LFU（14 days after end of treatment） | EA（Day 4） 、EOT（End of treatment）、TOC（7 days after end of treatment） and LFU（14 days after end of treatment） | |
| Secondary | Percentage of Participants With Microbiological Eradication at EA （Day 4）、EOT（End of treatment）、TOC（7 days after end of treatment） and LFU（14 days after end of treatment） Per Uropathogen | EA （Day 4）、EOT（End of treatment）、TOC（7 days after end of treatment） and LFU（14 days after end of treatment） Per Uropathogen | |
| Secondary | Percentage of Participants With Clinical Response at EA（Day 4） 、EOT（End of treatment）、TOC（7 days after end of treatment） and LFU（14 days after end of treatment） | EA（Day 4） 、EOT（End of treatment）、TOC（7 days after end of treatment） and LFU（14 days after end of treatment） | |
| Secondary | Percentage of Participants With Clinical Response at EA（Day 4） 、EOT（End of treatment）、TOC（7 days after end of treatment） and LFU （14 days after end of treatment）Per Uropathogen | EA（Day 4） 、EOT（End of treatment）、TOC（7 days after end of treatment） and LFU （14 days after end of treatment）Per Uropathogen |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06144060
GET https://conductscience.org/api/trials/v1/NCT06144060/registered